Navigation Links
Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes
Date:10/8/2007

LONDON, October 8 /PRNewswire/ -- Innovation in the pharma industry is not at a standstill: it has changed direction. Where once small molecule research provided the mainstay of companies' profits, biological drugs are now making their presence felt. While the range of genomic sciences waits to make its impact, biologicals are providing the current focus for novel discovery. Yet biologicals do not behave like small molecules; the rules for their development are different and they are often little understood.

The 2007 update to the Scrip Report 'How Drugs are Developed' responds to these changes. First published four years ago, and revised in 2005, the Report aims to inform all those involved with pharmaceutical R&D how each of the necessary disciplines fit together to take a new medicine from discovery to market launch.

Sections of the Report that previously focused on small molecules have now been expanded to describe the corresponding processes for biologicals. To increase its value even further, the 2007 update features two brand new chapters. The first deals with project management: the fundamentals of managing multidisciplinary teams and the ways in which the role is changing to encompass external as well as internal interfaces. The second concerns the growing interest in translational research; the ways in which laboratory concepts can be converted into medical advances.

The 234-page update retains all the Report's original sections, giving readers a firm grounding in all the stages of drug development from drug target hunting, lead generation and optimisation through to preclinical research, clinical evaluation and post-marketing surveillance. It also gives a step-by-step account of the various stages of preparing for drug development and the processes involved in making regulatory submissions. The Report also includes over 60 figures all of which serve to aid the reader's understanding of the issues discussed.

When the first edition of the Report was published in 2003, the impact of sequencing the human genome was just being felt throughout the industry. Now, in 2007, it is apparent that while providing promise for the future, there will be no 'quick fix' for the industry and it must pursue an ever wider range of opportunities to achieve its goals. The result is a networked industry without historical parallel.

Scrip Reports publishes an extensive range of pharmaceutical therapeutic market reports, detailed analyses of the pharmaceutical market for specific geographic areas, in-depth profiles of companies operating in the industry, financial and statistical analyses, directories and other strategic reports on the healthcare sector.

Visit http://www.scripreports.com.

For further press details contact

Jenefer Trevena

Managing Editor

Scrip Publishing

Tel: +44-(0)20-7017-6989

Email: jenefer.trevena@informa.com.

To purchase How Drugs are Developed 2007, contact:

Andrew Maitland

Sales Manager

Tel: +44-(0)20-7017-6859

Email: andrew.maitland@informa.com

quote code JR20004P.


'/>"/>
SOURCE Scrip Reports
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge unveils updated medical imaging software
2. Dane County mapping software updated, available to public
3. Lands End Debuts Updated Virtual Model
4. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
5. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
6. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
7. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
8. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
9. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
10. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):